Will New CEOs Make C-Suite More 'She-Suite'?
Improving gender balance in top pharma is a slow process, but not a gradual one. Management shake-ups often implemented by newly appointed CEOs could help.
You may also be interested in...
MedImmune's Bahija Jallal On Changing The Diversity Narrative
Bahija Jallal, vice president of AstraZeneca and head of MedImmune, told a packed room of mostly female health care employees that in her career she has "followed her heart and the science" to reach goals she had not imagined possible, as she accepted the Healthcare Businesswomen's Association's 2017 Woman of the Year award.
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.